(BPT) – Atopic dermatitis, also known as eczema, is a skin condition that may affect people of all races and ethnicities, but may occur more frequently in African-American children. According to US research, 19.3 percent of African-American children have eczema compared to 16.1 percent of European-American children. There are many different treatment options available to consider when taking into account the unique characteristics of each patient. Here are some facts to help understand eczema.
1. Eczema may present itself differently on everybody. Eczema commonly appears as dry, scaly, or red skin, and is often accompanied by oozing, crusted bumps; however, it may appear differently on different people.,, The face, neck, wrists, and ankles are common sites for many people, depending on age. Places where your body bends—like your elbows or back of your knees—are also common areas affected. For those of African descent, eczema may be more prevalent on the outer parts of the arms and legs. It is important to understand that eczema can also lead to issues such as dyspigmentation, which is skin discoloration that may be more apparent on darker skin tones.
2. Stay moisturized and avoid triggers. It is important to know what works best for your skin. Moisturizers, such as creams, ointments, oils, gels, and lotion can help keep your skin moisturized. Typical eczema triggers may include irritants (soaps, detergents, sweat, and rough fabrics), allergens (some types of food, dust mites, pollens), and environmental (temperature extremes, high or low humidity)., It may be helpful to track your flares in a notebook to help guide your conversation with your doctor.
3. Connect with the community for support. A large community of people living with or caring for someone with eczema is only a few clicks away on social media. Platforms such as Facebook and Instagram allow people living with the skin disease to find support, connect with other patients, and share their own personal stories.
4. Talk to your doctor about your options. It is important to discuss available treatment options with your doctor. EUCRISA® (crisaborole) ointment, 2% is a steroid-free treatment for mild-to-moderate eczema in adults and kids as young as two. EUCRISA can be used on all skin tones.
EUCRISA is a topical treatment that can be used nose to toes. EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth or vagina. It works above and below the skin to treat eczema. The active ingredient in EUCRISA is crisaborole 2%, which acts deep within skin cells to target phosphodiesterase 4 (PDE4). PDE4 is an enzyme that helps to regulate inflammation in your body. When you have eczema, PDE4 enzymes may be overactive in your skin cells. This can lead to inflammation in your skin. Reducing PDE4 activity decreases substances in your skin that are thought to cause inflammation related to eczema.,, The specific way EUCRISA works is not well defined.
IMPORTANT SAFETY INFORMATION & INDICATION
Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.
EUCRISA may cause side effects including allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. If you have any of these symptoms, stop using EUCRISA and get medical help right away.
The most common side effect of EUCRISA is application site pain, such as burning or stinging.
EUCRISA is for use on skin (topical use) only. Do not use EUCRISA in your eyes, mouth, or vagina.
EUCRISA is a prescription ointment used on the skin (topical) to treat mild-to-moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.
The information above, along with the treatment regimen that you and your doctor decide upon, may help provide a better understanding of your eczema. If you have additional questions, be sure to speak with your doctor.
For more information about EUCRISA, visit www.EUCRISA.com or call 1-866-EUCRISA (1-866-382-7472).
The EUCRISA Copay Savings Card is now available for eligible patients for as little as $10.* You can receive your card by texting EOFFER4 to 42762 or by visiting our website: https://www.eucrisa.com/eucrisa-4-you.
By opting into the EUCRISA mobile program, you consent to receive up to 10 marketing or not-marketing text messages and/or push notifications per month from Pfizer Inc., such as refill reminders, fill confirmation and website information.
*See terms and conditions. Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $700 per tube. Annual savings up to $2,800. This Card will be accepted only at participating pharmacies. This Card is not health insurance.
Eucrisa.com 1-866-382-7472 Pfizer Inc. PO Box 29387, Mission, KS 66201
This article is sponsored by Pfizer Inc.
 Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups- variations in epidemiology, genetics, clinical presentation and treatment. Experimental Dermatology. 2018;27:340-357.
 Bieber T. Atopic dermatitis. Dermatol. 2012;1(3):203-217.
 Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allerg Clin Immunol. 2006;118:152-169.
 Siegfried EC, Hebert AA. Diagnosis of atopic dermatitis: mimics, overlaps and complications. J Clin Med. 2015;4(5):884-917.
 Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015;32(6):409-420.
 EUCRISA® (crisaborole). Full Prescribing Information. October 2017.
 Jarnagin K, Chanda S, Coronado D, Ciaravino V, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390-396.
 Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993;91(6):1179-1188.
 Sawai T, Uehara M. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correction with respiratory atopy. Br J Dermatol. 1998;138(5):846-848.
 Eichenfield LF, Tom WL, Berger TG, Krol A, et al. Guidelines of care for the management of atopic dermatitis. Section 2: management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.